tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

BLTE Stock Latest News

Belite Bio initiated with an Overweight at Morgan Stanley
The FlyBelite Bio initiated with an Overweight at Morgan Stanley
8d ago
BLTE
Belite Bio: Tinlarebant’s First-Mover Advantage in STGD1 Supports Multi‑Billion Revenue Outlook and Further Upside Potential
PremiumRatings
Belite Bio: Tinlarebant’s First-Mover Advantage in STGD1 Supports Multi‑Billion Revenue Outlook and Further Upside Potential
8d ago
BLTE
Belite Bio participates in a conference call with H.C. Wainwright
PremiumThe Fly
Belite Bio participates in a conference call with H.C. Wainwright
27d ago
BLTE
Belite Bio Prices $350 Million ADS Offering to Boost Drug Development
PremiumCompany Announcements
Belite Bio Prices $350 Million ADS Offering to Boost Drug Development
1M ago
6K
BLTE
Belite Bio price target raised to $200 from $140 at Maxim
PremiumThe Fly
Belite Bio price target raised to $200 from $140 at Maxim
1M ago
BLTE
Belite Bio 2.273M share Spot Secondary priced at $154.00
PremiumThe FlyBelite Bio 2.273M share Spot Secondary priced at $154.00
1M ago
BLTE
Mizuho upgrades Belite to Buy on ‘impressive’ Stargardt data
Premium
The Fly
Mizuho upgrades Belite to Buy on ‘impressive’ Stargardt data
1M ago
BLTE
Belite Bio upgraded to Outperform from Neutral at Mizuho
Premium
The Fly
Belite Bio upgraded to Outperform from Neutral at Mizuho
1M ago
BLTE
Belite Bio TBA Spot Secondary; price range $150.00-$154.00
PremiumThe Fly
Belite Bio TBA Spot Secondary; price range $150.00-$154.00
1M ago
BLTE
Belite Bio Reports Increased Cash Reserves Amid Rising R&D Costs
PremiumCompany Announcements
Belite Bio Reports Increased Cash Reserves Amid Rising R&D Costs
1M ago
6K
BLTE
Belite Bio Announces Public Offering of ADSs to Fund Expansion
PremiumCompany Announcements
Belite Bio Announces Public Offering of ADSs to Fund Expansion
1M ago
6K
BLTE
Belite Bio announces American Depositary shares offering, no amount given
PremiumThe Fly
Belite Bio announces American Depositary shares offering, no amount given
1M ago
BLTE
Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
PremiumMarket NewsMorning News Wrap-Up: Monday’s Biggest Stock Market Stories!
1M ago
HD
LI
Positive Outlook for Belite Bio: Promising Phase 3 Results and Increased Approval Probability for Tinlarebant
Premium
Ratings
Positive Outlook for Belite Bio: Promising Phase 3 Results and Increased Approval Probability for Tinlarebant
1M ago
BLTE
Belite Bio price target raised to $185 from $98 at H.C. Wainwright
Premium
The Fly
Belite Bio price target raised to $185 from $98 at H.C. Wainwright
1M ago
BLTE
Belite Bio Stock (BLTE) Jumps on Positive Phase 3 STGD1 Trial Data
PremiumMarket News
Belite Bio Stock (BLTE) Jumps on Positive Phase 3 STGD1 Trial Data
1M ago
BLTE
Belite Bio Reports Breakthrough Phase 3 Results for Stargardt Disease Treatment
PremiumCompany Announcements
Belite Bio Reports Breakthrough Phase 3 Results for Stargardt Disease Treatment
1M ago
6K
BLTE
Belite Bio says tinlarebant met primary efficacy endpoint in Phase 3 trial
PremiumThe Fly
Belite Bio says tinlarebant met primary efficacy endpoint in Phase 3 trial
1M ago
BLTE
Belite Bio falls -9.3%
PremiumThe Fly
Belite Bio falls -9.3%
2M ago
BLTE
Belite Bio rises 16.3%
PremiumThe FlyBelite Bio rises 16.3%
2M ago
BLTE
Belite Bio assumed with an Overweight at Cantor Fitzgerald
Premium
The Fly
Belite Bio assumed with an Overweight at Cantor Fitzgerald
2M ago
BLTE
Astera initiated, Nasdaq upgraded: Wall Street’s top analyst calls
Premium
The Fly
Astera initiated, Nasdaq upgraded: Wall Street’s top analyst calls
2M ago
ES
APO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >